1 Report Overview
1.1 Study Scope
1.2 Key Market Segments
1.3 Players Covered: Ranking by Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue
1.4 Market Analysis by Type
1.4.1 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Size Growth Rate by Type: 2020 VS 2026
1.4.2 Preface
1.4.3 Eluxadoline
1.4.4 Alosetron
1.4.5 Rifaximin
1.4.6 Loperamide
1.4.7 Diphenoxylate + Atropine
1.4.8 Dicyclomine and Hyoscyamine
1.5 Market by Application
1.5.1 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Share by Application: 2021-2026
1.5.2 Hospitals
1.5.3 Clinics
1.5.4 Others
1.6 Study Objectives
1.7 Years Considered
1.8 Overview of Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market
1.8.1 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Status and Outlook (2015-2026)
1.8.2 North America
1.8.3 East Asia
1.8.4 Europe
1.8.5 South Asia
1.8.6 Southeast Asia
1.8.7 Middle East
1.8.8 Africa
1.8.9 Oceania
1.8.10 South America
1.8.11 Rest of the World
2 Market Competition by Manufacturers
2.1 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Production Capacity Market Share by Manufacturers (2015-2020)
2.2 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Market Share by Manufacturers (2015-2020)
2.3 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Average Price by Manufacturers (2015-2020)
2.4 Manufacturers Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Production Sites, Area Served, Product Type
3 Sales by Region
3.1 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Volume Market Share by Region (2015-2020)
3.2 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Revenue Market Share by Region (2015-2020)
3.3 North America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Volume
3.3.1 North America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Volume Growth Rate (2015-2020)
3.3.2 North America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Volume Capacity, Revenue, Price and Gross Margin (2015-2020)
3.4 East Asia Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Volume
3.4.1 East Asia Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Volume Growth Rate (2015-2020)
3.4.2 East Asia Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Volume Capacity, Revenue, Price and Gross Margin (2015-2020)
3.5 Europe Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Volume (2015-2020)
3.5.1 Europe Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Volume Growth Rate (2015-2020)
3.5.2 Europe Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Volume Capacity, Revenue, Price and Gross Margin (2015-2020)
3.6 South Asia Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Volume (2015-2020)
3.6.1 South Asia Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Volume Growth Rate (2015-2020)
3.6.2 South Asia Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Volume Capacity, Revenue, Price and Gross Margin (2015-2020)
3.7 Southeast Asia Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Volume (2015-2020)
3.7.1 Southeast Asia Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Volume Growth Rate (2015-2020)
3.7.2 Southeast Asia Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Volume Capacity, Revenue, Price and Gross Margin (2015-2020)
3.8 Middle East Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Volume (2015-2020)
3.8.1 Middle East Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Volume Growth Rate (2015-2020)
3.8.2 Middle East Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Volume Capacity, Revenue, Price and Gross Margin (2015-2020)
3.9 Africa Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Volume (2015-2020)
3.9.1 Africa Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Volume Growth Rate (2015-2020)
3.9.2 Africa Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Volume Capacity, Revenue, Price and Gross Margin (2015-2020)
3.10 Oceania Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Volume (2015-2020)
3.10.1 Oceania Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Volume Growth Rate (2015-2020)
3.10.2 Oceania Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Volume Capacity, Revenue, Price and Gross Margin (2015-2020)
3.11 South America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Volume (2015-2020)
3.11.1 South America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Volume Growth Rate (2015-2020)
3.11.2 South America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Volume Capacity, Revenue, Price and Gross Margin (2015-2020)
3.12 Rest of the World Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Volume (2015-2020)
3.12.1 Rest of the World Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Volume Growth Rate (2015-2020)
3.12.2 Rest of the World Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Volume Capacity, Revenue, Price and Gross Margin (2015-2020)
4 North America
4.1 North America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Consumption by Countries
4.2 United States
4.3 Canada
4.4 Mexico
5 East Asia
5.1 East Asia Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Consumption by Countries
5.2 China
5.3 Japan
5.4 South Korea
6 Europe
6.1 Europe Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Consumption by Countries
6.2 Germany
6.3 United Kingdom
6.4 France
6.5 Italy
6.6 Russia
6.7 Spain
6.8 Netherlands
6.9 Switzerland
6.10 Poland
7 South Asia
7.1 South Asia Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Consumption by Countries
7.2 India
7.3 Pakistan
7.4 Bangladesh
8 Southeast Asia
8.1 Southeast Asia Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Consumption by Countries
8.2 Indonesia
8.3 Thailand
8.4 Singapore
8.5 Malaysia
8.6 Philippines
8.7 Vietnam
8.8 Myanmar
9 Middle East
9.1 Middle East Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Consumption by Countries
9.2 Turkey
9.3 Saudi Arabia
9.4 Iran
9.5 United Arab Emirates
9.6 Israel
9.7 Iraq
9.8 Qatar
9.9 Kuwait
9.10 Oman
10 Africa
10.1 Africa Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Consumption by Countries
10.2 Nigeria
10.3 South Africa
10.4 Egypt
10.5 Algeria
10.6 Morocco
11 Oceania
11.1 Oceania Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Consumption by Countries
11.2 Australia
11.3 New Zealand
12 South America
12.1 South America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Consumption by Countries
12.2 Brazil
12.3 Argentina
12.4 Columbia
12.5 Chile
12.6 Venezuela
12.7 Peru
12.8 Puerto Rico
12.9 Ecuador
13 Rest of the World
13.1 Rest of the World Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Consumption by Countries
13.2 Kazakhstan
14 Sales Volume, Sales Revenue, Sales Price Trend by Type
14.1 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Volume Market Share by Type (2015-2020)
14.2 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Revenue Market Share by Type (2015-2020)
14.3 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Price by Type (2015-2020)
15 Consumption Analysis by Application
15.1 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Consumption Volume by Application (2015-2020)
15.2 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Consumption Value by Application (2015-2020)
16 Company Profiles and Key Figures in Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Business
16.1 Astellas Pharmaceuticals
16.1.1 Astellas Pharmaceuticals Company Profile
16.1.2 Astellas Pharmaceuticals Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Product Specification
16.1.3 Astellas Pharmaceuticals Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Production Capacity, Revenue, Price and Gross Margin (2015-2020)
16.2 GlaxoSmithKline
16.2.1 GlaxoSmithKline Company Profile
16.2.2 GlaxoSmithKline Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Product Specification
16.2.3 GlaxoSmithKline Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Production Capacity, Revenue, Price and Gross Margin (2015-2020)
16.3 Actavis
16.3.1 Actavis Company Profile
16.3.2 Actavis Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Product Specification
16.3.3 Actavis Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Production Capacity, Revenue, Price and Gross Margin (2015-2020)
16.4 Pfizer
16.4.1 Pfizer Company Profile
16.4.2 Pfizer Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Product Specification
16.4.3 Pfizer Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Production Capacity, Revenue, Price and Gross Margin (2015-2020)
16.5 AstraZenenca
16.5.1 AstraZenenca Company Profile
16.5.2 AstraZenenca Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Product Specification
16.5.3 AstraZenenca Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Production Capacity, Revenue, Price and Gross Margin (2015-2020)
16.6 Salix Pharmaceuticals Ltd
16.6.1 Salix Pharmaceuticals Ltd Company Profile
16.6.2 Salix Pharmaceuticals Ltd Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Product Specification
16.6.3 Salix Pharmaceuticals Ltd Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Production Capacity, Revenue, Price and Gross Margin (2015-2020)
17 Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Manufacturing Cost Analysis
17.1 Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Key Raw Materials Analysis
17.1.1 Key Raw Materials
17.2 Proportion of Manufacturing Cost Structure
17.3 Manufacturing Process Analysis of Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs
17.4 Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Industrial Chain Analysis
18 Marketing Channel, Distributors and Customers
18.1 Marketing Channel
18.2 Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Distributors List
18.3 Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Customers
19 Market Dynamics
19.1 Market Trends
19.2 Opportunities and Drivers
19.3 Challenges
19.4 Porter's Five Forces Analysis
20 Production and Supply Forecast
20.1 Global Forecasted Production of Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs (2021-2026)
20.2 Global Forecasted Revenue of Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs (2021-2026)
20.3 Global Forecasted Price of Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs (2015-2026)
20.4 Global Forecasted Production of Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs by Region (2021-2026)
20.4.1 North America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Production, Revenue Forecast (2021-2026)
20.4.2 East Asia Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Production, Revenue Forecast (2021-2026)
20.4.3 Europe Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Production, Revenue Forecast (2021-2026)
20.4.4 South Asia Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Production, Revenue Forecast (2021-2026)
20.4.5 Southeast Asia Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Production, Revenue Forecast (2021-2026)
20.4.6 Middle East Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Production, Revenue Forecast (2021-2026)
20.4.7 Africa Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Production, Revenue Forecast (2021-2026)
20.4.8 Oceania Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Production, Revenue Forecast (2021-2026)
20.4.9 South America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Production, Revenue Forecast (2021-2026)
20.4.10 Rest of the World Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Production, Revenue Forecast (2021-2026)
20.5 Forecast by Type and by Application (2021-2026)
20.5.1 Global Sales Volume, Sales Revenue and Sales Price Forecast by Type (2021-2026)
20.5.2 Global Forecasted Consumption of Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs by Application (2021-2026)
21 Consumption and Demand Forecast
21.1 North America Forecasted Consumption of Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs by Country
21.2 East Asia Market Forecasted Consumption of Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs by Country
21.3 Europe Market Forecasted Consumption of Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs by Countriy
21.4 South Asia Forecasted Consumption of Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs by Country
21.5 Southeast Asia Forecasted Consumption of Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs by Country
21.6 Middle East Forecasted Consumption of Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs by Country
21.7 Africa Forecasted Consumption of Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs by Country
21.8 Oceania Forecasted Consumption of Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs by Country
21.9 South America Forecasted Consumption of Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs by Country
21.10 Rest of the world Forecasted Consumption of Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs by Country
22 Research Findings and Conclusion
23 Methodology and Data Source
23.1 Methodology/Research Approach
23.1.1 Research Programs/Design
23.1.2 Market Size Estimation
23.1.3 Market Breakdown and Data Triangulation
23.2 Data Source
23.2.1 Secondary Sources
23.2.2 Primary Sources
23.3 Disclaimer